EnteroMix: Promise and Peril in Russia’s Personalized Cancer Vaccine

Document text

By Peter A. McCullough, MD, MPHThe news was buzzing about a Russian cancer vaccine back in 2024-25.  But the story has gone cold in 2026; I wondered why?🔬 How It WorksEnteroMix is a Russian-developed therapeutic cancer vaccine combining two strategies. The first is anoncolytic viral cocktail— four replication-competent enteroviruses (CVA21, ECHO-7, EV-B75, and a poliovirus–rhinovirus chimera) that selectively infect and lyse tumor cells, releasing antigens and danger signals that “heat” the tumor microenvironment. The second is apersonalized mRNA vaccine— synthesized from the patient’s own tumor RNA — that encodes patient-specific neoantigens, training T-cells to hunt cancer cells bearing those mutational signatures.Subscribe nowRead more